Boston Trust Walden Corp Sells 4,169 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Boston Trust Walden Corp trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 196,145 shares of the medical research company’s stock after selling 4,169 shares during the period. Boston Trust Walden Corp owned about 0.38% of Charles River Laboratories International worth $38,635,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. raised its holdings in shares of Charles River Laboratories International by 1,072.7% in the first quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock worth $70,000 after buying an additional 236 shares during the period. Congress Wealth Management LLC DE increased its stake in Charles River Laboratories International by 0.9% in the first quarter. Congress Wealth Management LLC DE now owns 54,316 shares of the medical research company’s stock worth $14,717,000 after purchasing an additional 500 shares during the period. Woodmont Investment Counsel LLC bought a new stake in shares of Charles River Laboratories International during the first quarter worth $218,000. Norden Group LLC boosted its stake in shares of Charles River Laboratories International by 2,642.3% during the first quarter. Norden Group LLC now owns 31,399 shares of the medical research company’s stock valued at $8,508,000 after purchasing an additional 30,254 shares during the period. Finally, First Trust Direct Indexing L.P. purchased a new stake in shares of Charles River Laboratories International during the first quarter valued at $211,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CRL shares. The Goldman Sachs Group decreased their price objective on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered Charles River Laboratories International from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $270.00 to $205.00 in a report on Thursday, August 8th. Redburn Atlantic began coverage on Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 price objective on the stock. TD Cowen lowered their target price on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a report on Monday, August 12th. Finally, Bank of America lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price target for the company from $250.00 to $215.00 in a research note on Wednesday, October 2nd. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Trading Down 0.3 %

NYSE:CRL opened at $182.12 on Friday. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of 21.43, a PEG ratio of 5.11 and a beta of 1.36. Charles River Laboratories International, Inc. has a 52 week low of $161.65 and a 52 week high of $275.00. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $195.84 and a 200 day moving average of $211.33.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its board has initiated a stock buyback plan on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).